[8-K] CVS HEALTH Corp Reports Material Event

Rhea-AI Filing Summary

CVS Health Corporation furnished information from its 2025 Investor Day, where it discussed strategic priorities and updated its financial outlook. On December 9, 2025, the company issued a press release that revised its full-year 2025 financial guidance and introduced full-year 2026 financial guidance. The press release is attached as Exhibit 99.1 to this report and is incorporated into the Regulation FD disclosure section by reference.

The company notes that this press release and related information are being furnished, not filed, under securities laws, meaning they are not automatically subject to certain liability provisions or incorporated into other securities filings unless specifically referenced.

0000064803false00000648032025-12-092025-12-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2025

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)

Delaware			001-01011			05-0494040
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

One CVS Drive, Woonsocket, Rhode Island						02895
(Address of principal executive offices)						(Zip Code)
Registrant’s telephone number, including area code:						(401) 765-1500
Former name or former address, if changed since last report:						N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.01 per share			CVS			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐

Section 7 - Regulation FD

Item 7.01 Regulation FD Disclosure.

In connection with its 2025 Investor Day, on December 9, 2025, CVS Health Corporation issued a press release that, among other things, discussed its strategic priorities, updated its 2025 full-year financial guidance and provided its 2026 full-year financial guidance. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 7.01 by reference.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS

			99.1			Press Release of CVS Health Corporation dated December 9, 2025
			104			Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									CVS HEALTH CORPORATION
Date:			December 9, 2025			By:			/s/ Brian O. Newman
									Brian O. Newman
									Executive Vice President and Chief Financial Officer